Pharmacopeia Considers Splitting Accelrys from Drug Discovery Business | GenomeWeb

NEW YORK, July 12 - Pharmacopeia said Thursday that it is considering splitting its software business, Accelrys, off from its drug discovery businesses, as well as other strategic alternatives, to help the drug discovery operations expand independently of its collaborators and access a greater number of drug targets.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."